Coregulators mediate selective interactions between DNA-bound androgen receptor and other transcription factors, which control distinct prostate cancer biology, suggesting disruption of critical interactions in these complexes as a novel therapeutic strategy.

Three new protein markers of testosterone action identified by us, may prove to be valuable as clinical tools in identifying men with testosterone deficiency and in monitoring androgen replacement therapy.

Analyses of genetically engineered mouse models reveal the androgen receptor-independent properties of a luminal stem/progenitor cell in the prostate epithelium, and its ability to serve as a cell of origin for castration-resistant prostate cancer.

Augmentation of progestin signaling promotes testis development and spermatogenesis independent from andorgen signaling in zebrafish.

DECR1, a rate-limiting enzyme for polyunsaturated fatty acid (PUFA) β-oxidation, is an androgen-repressed gene in prostate cancer cells that limits oxidative stress to promote cancer cell survival.

Epigenetic clocks are an accurate measure of biological aging and 'tick' slower in male sheep that are castrated.

The rational drug design combining the bioassay identified a novel selective androgen receptor (AR) degrader for both AR and AR-VRs and illustrated the synergistic importance of AR antagonism and degradation in advanced prostate cancer treatment.

Targeting the activation of the androgen receptor N-terminal domain by the cochaperone Bag-1L provides a new approach for inhibiting androgen receptor function to treat prostate cancer.

A positive feedback loop between the androgen receptor and a key pentose phosphate pathway enzyme, 6PGD, in prostate cancer promotes tumour cell proliferation, survival and intracellular redox control.

A comprehensive molecular interrogation of CREB5 interactions identified changes in protein and chromatin interactions of FOXA1 that promoted therapy resistance in prostate cancer cells.